For subjective evaluation the trial design will be on a double blinding level, which means that neither patients nor expert clinicians will know which treatment the patients are randomized to. This can be achieved by concealing allocation information from patients and by using expert clinicians, who are otherwise not involved in the patients' care, to assess treatment difficulties and outcomes without knowing their treatment group.